Media OutReach Newswire

2024-07-30 17:20

ZEISS Adopts PolyU's Patented Technology to Develop ZEISS MyoCare Myopia Control Lenses for Children

Professional ophthalmic products feature patented myopia control technology, effectively slowing down myopia progression in nearly 90% of child wearers

HONG KONG SAR - Media OutReach Newswire - 30 July 2024 - ZEISS Vision Care (ZEISS) and the School of Optometry of The Hong Kong Polytechnic University (PolyU) announced their latest collaborative initiative, ZEISS MyoCare Myopia Control Spectacle Lenses (ZEISS MyoCare Lenses). The lenses utilize PolyU's patented Defocus Incorporated Soft Contact (DISC) technology for myopia management. Through this collaboration, the two parties joined forces to drive better control and management of myopia in children globally. This collaboration has enabled ZEISS to adopt PolyU's patented DISC technology in its specialist optical products, integrating authoritative academic ophthalmic research with cutting-edge ophthalmological technology to provide the public with new effective professional vision care solutions.

ZEISS Vision Care (ZEISS) and the School of Optometry of The Hong Kong Polytechnic University (PolyU) announced their latest collaborative initiative, ZEISS MyoCare Lenses, featuring (From left to right) Prof. Kee Chea-su, Head, School of Optometry, PolyU; Prof. Christopher Chao, Vice President (Research and Innovation), PolyU; Mr. David Ferran, Vice president, Latin America, Iberia & Asia -C, Vision Care Business Group, ZEISS and Mr Jerome Chan, Siu Lung, Head of Vision Care SBU, Hong Kong & Macau, ZEISS.
ZEISS Vision Care (ZEISS) and the School of Optometry of The Hong Kong Polytechnic University (PolyU) announced their latest collaborative initiative, ZEISS MyoCare Lenses, featuring (From left to right) Prof. Kee Chea-su, Head, School of Optometry, PolyU; Prof. Christopher Chao, Vice President (Research and Innovation), PolyU; Mr. David Ferran, Vice president, Latin America, Iberia & Asia -C, Vision Care Business Group, ZEISS and Mr Jerome Chan, Siu Lung, Head of Vision Care SBU, Hong Kong & Macau, ZEISS.

ZEISS MyoCare Lenses uses PolyU's DISC technology[1], its patented design adds a set of specialized optical microstructures to the general refractive myopia correction optical structure. The two sets of optical structures are arranged alternately on the lens surface. The corrective area projects the image onto the retina, allowing the wearer to see a clear image, while the optical microstructures project another set of images in front of the retina, i.e., the "forward optical defocus" signal, utilizing the eye's natural emmetropization feedback mechanism to guide the eye and slow down the growth of the eyeball axis of myopic patients. The technology is completely non-invasive and has undergone multiple basic experiments and clinical verifications, proven to be safe, effective and without significant side effects.

ZEISS MyoCare Lenses also incorporate patented ZEISS C.A.R.E.® technology. It can effectively decelerate the rate of myopia progression by 48% to 63% and diminish axial length increase by 41% to 77%[2],[3]. Furthermore, these lenses provide wearers with clear vision regardless of viewing distance and direction, and are easy to adapt to, with over 95% of child wearers able to adapt to the lenses within three days[4],[5].

A recent 12-month research report shows that nearly 90% of children wearing ZEISS MyoCare Lenses experienced slow annual myopia progression, compared to 51% of children wearing single vision lenses experiencing fast progression[6]. Moreover, ZEISS MyoCare lenses slowed eye growth from that of a myopic eye to approach that of an emmetropic eye by nearly 70%[7].

Mitigating the Risk of Myopia Progression in Children with Parental Myopia
Research confirmed that genetic factors, such as having parents with myopia, increases a child's risk of developing myopia. However, a 12-month clinical study has shown that compared to wearing regular single vision lenses, using ZEISS MyoCare Lenses can effectively slow down myopia progression, even for children with myopic parents, who are especially at risk of developing myopia[8]. This indicates that these lenses can help parents with myopia reduce the increased risk of myopia development in their children, essentially breaking the cycle of worsening myopia each generation.

Professor Christopher Chao, Vice President (Research and Innovation) of The Hong Kong Polytechnic University, said, "PolyU has always been committed to promoting technology transfer. The DISC technology for myopia management is an excellent example to demonstrate how academic research can be transformed into effective industry solutions, offering an additional option in the market for those in need. It is a great pleasure to collaborate with ZEISS, a leading optical brand, to jointly strive for excellence in the development of myopia control for the benefit of community."

David Ferran, Head of LatAm, Iberia & Asia-C, Vision Care Business, ZEISS Group, added, "ZEISS has been working closely with PolyU for many years. Through this collaboration, we will jointly develop more innovative technologies, aiming to bring the best ophthalmological technology into vision correction solutions, collectively addressing the threat posed by myopia and promoting the well-being of children worldwide."

Calvin Kwan, President of The Hong Kong Optometric Association, said: "Myopia is a serious issue among Hong Kong children, and age six to 12 years old is the 'golden period' for myopia control. Parents should seize the opportunity to provide the best and most effective myopia control measures for their children, safeguarding their eye health and preventing the development of high myopia and other long-term eye health problems."

The Trusted Choice for Parents – Backed by Scientific Research
Parents' testimonials: "In this digital age, it is practically impossible to completely avoid exposing our children to electronic devices, especially with the widespread adoption of e-learning in schools. As parents, we want to provide the best protection for our children, ensuring they have healthy eyes to see the future more clearly and far. Aligned with the needs of the current era, the issue of myopia control in children is a key eye health concern that parents need to address."

Parents' selection criteria: "When it comes to selecting lenses for myopia control, the primary consideration is the effectiveness and whether it is supported by scientific research. Since the 'golden period' for children's myopia control is only about six years, if we are unable to select and use scientifically proven products in a timely manner, the effect of slowing down myopia progression will be greatly diminished, and the precious golden period from age six to 12 will be missed.

The ZEISS MyoCare Lenses are supported by real data, which not only gives me confidence in the product, but also allows me, through this myopia control solution, to work more closely with the optometrist to address my child's myopia progression. I believe parents play a very important role in protecting the eye health of their children."



[1] Hong Kong Polytechnic University owns granted patents (including Chinese patent: CN103097940) on annular concentric lens for myopia control, which are licensed to Carl Zeiss..

[2] Compared to ZEISS single vision lenses, after 12 months of wear, ZEISS MyoCare designs slowed myopia progression on average of 48% (MyoCare) and 45%(MyoCare S) for spherical equivalent error, and by 41%(MyoCare) and 34%(MyoCare S) for axial length. Chen, X., et al. (2024, May 5-9). Slowing myopia progression with cylindrical annular refractive elements (CARE) – 12-month interim results from a 2-year prospective multi-center trial [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.

[3] Compared to ZEISS single vision lenses, after 6 months of wear, ZEISS MyoCare slowed myopia progression on average of 0.15D (63%) for spherical equivalent error and 0.07mm (77%) for axial length. Alvarez-Peregrina, C., et al. (2024, May 5-9). Efficacy of a next-generation design of ophthalmic lenses for myopia control: Six-month results of the CEME Study [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.

[4] Rifai, K., et al. (2024, May 5-9). Subjective acceptance of spectacle lenses with cylindrical annular refractive elements (CARE) in Chinese children with myopia [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.

[5] Alvarez-Peregrina C., et al. (2024, April 12-14). Vision, confort y tiempo de adaptacion a un nuevo diseno de lente oftalmica para el control de miopia [Conference presentation abstract]. OPTOM 2024, Madrid, Spain.

[6] Sankaridurg, P., et al. (2024, May 5-9). Probability of surviving fast progression and eye growth reversal after 1-year of spectacle wear with cylindrical annular refractive elements [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.

[7] Twelve-months of lens wear, both ZEISS MyoCare lenses slowed AL significantly and approached closer to AL growth of an emmetropic eye, with average EPRs of 70%* for ZEISS MyoCare and 68% for ZEISS MyoCare S. Ohlendorf, A., et al. (2024, May 5-9). Myopia control efficacy through Emmetropic Progression Ratio:1-year of spectacle wear with cylindrical annular refractive elements (CARE) [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.

[8] Boeck-Maier, C., et al. (2024, May 5-9). Impact of parental myopia on myopia control efficacy of spectacle lenses with cylindrical annular refractive elements (CARE) [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Seattle, WA, United States.

Hashtag: #ZEISS #MyoCare

發佈者對本公告的內容承擔全部責任

About ZEISS

With a rich history spanning 175 years, ZEISS is recognized as one of the oldest and most esteemed optical brands worldwide. Throughout the past century, ZEISS has consistently led the market, offering unparalleled optical products and expert knowledge. As a visionary and iconic brand, ZEISS has always prioritized precision in the production of optical lenses, striving to become a lifelong partner in vision care for individuals. ZEISS' commitment lies in empowering people to see the world with utmost clarity. ZEISS proved that everyone's visual world is unique and that ZEISS understands people and their individual needs like no one else. Let's unlock everyone's full potential with premium vision and eye care solutions by ZEISS.

About the School of Optometry of The Hong Kong Polytechnic University

The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university with a strong sense of social responsibility, driven by its motto, "To learn and to apply, for the benefit of mankind". The University provides the best holistic education to nurture socially responsible "leaders of tomorrow" who possess a strong sense of national identity and a global perspective, and pursues impactful innovation and interdisciplinary research to address the world's most pressing challenges. A robust culture of knowledge transfer and entrepreneurship is a cornerstone of the University, ensuring PolyU's technologies are transformed into practical real-world applications. The University's unwavering commitment to excellence has earned it international recognition, with PolyU consistently ranking among the top 100 universities worldwide. Based on this solid foundation, the University will continue to make positive contributions in collaboration with its strategic partners for the betterment of Hong Kong, the Nation, and the world.

The PolyU School of Optometry is the only institution in Hong Kong that offers a bachelor's honours degree programme in optometry leading to a professional qualification as an optometrist in Hong Kong and the programme is regarded as one of the best in the world. As a globally top-ranking optometry department for research excellence, the School strives to undertake research-based teaching of the highest academic standards and to contribute to the promotion and delivery of high-quality vision and eye care in Hong Kong and elsewhere.

source: ZEISS and the School of Optometry of The Hong Kong Polytechnic University

【你點睇?】高拔陞指醫管局將採購內地醫療儀器配合政府節流,你是否支持?► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
4
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
5
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
6
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
7
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
8
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
9
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
10
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
11
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
12
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
13
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
14
一本萬利 | 2025年的五個「勿」(有片)
15
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
16
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
17
港股 | 蕭猷華:恒指春節前目標21500點
18
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
19
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
20
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
21
習近平應約與特朗普通電話,特:冀盡快與習見面
22
易經看世界 | 從乙巳年立春八字看香港前景:哪行業當旺?哪行業運滯?(有片)
23
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
24
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
25
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
26
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
27
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
28
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
29
加州山火造成超500億美元損失,大量房主未買保險
30
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老